EuroGo is a pilot project aimed at better care for Gaucher patients, set up by the AMC and FairMedicine. We were asked to develop and validate a scalable and sustainable business model for future growth.
The challenge of the EuroGo project was to develop and validate a scalable business model for future continuity of EuroGo. Through the establishment of a digital data registry, researchers gain access to more complete information, and patients will be able to better monitor their own health. As a result, better research and monitoring will improve the lives of people living with Gaucher’s disease. We were asked to develop a business model which is scalable and sustainable.
To develop a scalable and sustainable business model, we started with desk research on other existing inspirational business models. Simultaneously, we conducted stakeholder interviews to draw a stakeholder map. Soon we realized that in order to develop a sustainable business model scalability was crucial. We analyzed several scaling options and developed four different scenarios illustrating four scaling methods and their benefits and disadvantages.
Scaling European wide or scaling by developing entries for multiple (rare) chronic disease would both be beneficial to reach and improve the lives of more people living with a (rare) chronic disease. We have provided the AMC and FairMedicine with a clear insight into the various scaling options and revenue models.